{"filing":{"accession_number":"0001104659-26-106064","cik":"0001412558","ticker":"EVOTF","company_name":"Evotec SE","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"tm2625085d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412558/000110465926106064/tm2625085d1_6k.htm"},"events":[{"id":32145,"run_id":29526,"accession_number":"0001104659-26-106064","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The exhibit announces initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail developed under a U.S. Department of War contract. This represents a material operational and clinical milestone for Evotec's biologics subsidiary, demonstrating advancement of a government-funded biodefense program from development through manufacturing to first-in-human studies. While not a discrete M\u0026A, financing, or governance event, the clinical advancement of a material program under a contract with combined potential value of up to $123.9 million would affect a reasonable investor's assessment of the company's pipeline and operational capabilities.","company_name":"Evotec SE","ticker":"EVOTF","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35252,"accession_number":"0001104659-26-106064","item_number":"EX-99.1","item_title":"tm2625085d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The exhibit announces initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail developed under a U.S. Department of War contract. This represents a material operational and clinical milestone for Evotec's biologics subsidiary, demonstrating advancement of a government-funded biodefense program from development through manufacturing to first-in-human studies. While not a discrete M\u0026A, financing, or governance event, the clinical advancement of a material program under a contract with combined potential value of up to $123.9 million would affect a reasonable investor's assessment of the company's pipeline and operational capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:09:23.696306+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35252,"accession_number":"0001104659-26-106064","item_number":"EX-99.1","item_title":"tm2625085d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The exhibit announces initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail developed under a U.S. Department of War contract. This represents a material operational and clinical milestone for Evotec's biologics subsidiary, demonstrating advancement of a government-funded biodefense program from development through manufacturing to first-in-human studies. While not a discrete M\u0026A, financing, or governance event, the clinical advancement of a material program under a contract with combined potential value of up to $123.9 million would affect a reasonable investor's assessment of the company's pipeline and operational capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:09:23.696306+00:00","company_name":"Evotec SE","ticker":"EVOTF","filing_date":"2026-09-09"}]}